Business Context and Reporting Period
Company: Mustang Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 26, 2023 (Event Date); Signed October 30, 2023
Reporting Period: Specific event reporting regarding a capital raise closed on October 30, 2023.
Key Financial Metrics and Transaction Details
This filing details a capital raise consisting of a Registered Direct Offering and a concurrent Private Placement. The filing does not provide standard periodic financial metrics such as revenue, net income, or operating cash flow.
- Gross Proceeds: Approximately $4.4 million from the combined Offerings.
- Registered Offering:
- 920,000 shares of Common Stock at $1.70 per share.
- 1,668,236 Pre-funded Warrants at $1.699 per warrant (exercise price $0.001).
- Private Placement:
- 2,588,236 unregistered Warrants at $0.125 per warrant.
- Warrant Exercise Price: $1.58 per share (subject to adjustments).
- Warrant Expiration: 5.5 years from issuance.
- Placement Agent Fees (H.C. Wainwright & Co., LLC):
- Cash Fee: 7.0% of gross proceeds.
- Management Fee: 1.0% of gross proceeds.
- Expenses: $75,000 non-accountable expenses and $15,950 clearing fee.
- Warrants: 155,294 Wainwright Warrants (Exercise Price: $2.125; Expiration: 5 years).
Material Changes and Use of Proceeds
The primary material change is the increase in outstanding equity and potential dilution resulting from the issuance of shares and warrants. The Company intends to use the net proceeds for general corporate purposes and working capital, specifically to advance product candidates toward FDA regulatory approval.
Guidance, Risks, and Contingencies
- Beneficial Ownership Limitation: Holders cannot exercise warrants if it results in beneficial ownership exceeding 4.99% (or 9.99% at the purchaser's option) of outstanding Common Stock, unless 61 days' prior notice is given.
- Lock-up Restrictions: The Company is restricted from issuing or selling Common Stock or Common Stock Equivalents for 45 days following the closing of the offering.
- Registration Requirement: The Company must file a resale registration statement for shares issuable upon exercise of the Warrants.
- Risk Factors: The filing includes standard forward-looking statement disclaimers regarding drug development risks, clinical trial uncertainties, and regulatory approval timelines. It references the Risk Factors section of the Company's 2023 Form 10-K.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8% cash fees, expenses, and warrant issuance costs.
- Confirm the total number of shares outstanding post-offering to assess immediate dilution impact.
- Review the specific terms of the anti-dilution adjustments in the Warrants and Pre-funded Warrants.
- Monitor the Company's cash burn rate relative to the $4.4 million raised to determine runway for clinical trials.
- Check for the filing of the required resale registration statement for the Warrants.